FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992023011> ?p ?o ?g. }

• W1992023011 endingPage "1234" @default.
• W1992023011 startingPage "1228" @default.
• W1992023011 abstract "During the pandemic of the 2009 A(H1N1) influenza virus strain, 20-40% of the population in some areas were infected. Infection with A(H1N1) may be mild, with an average case fatality rate below 0.25%, but severe disease is not limited to patients with underlying medical conditions. Since A(H1N1) is expected to continue to circulate it is included in the seasonal influenza vaccines for the 2010-2011 winter season. We investigated the immunogenicity and safety of a preservative-free non-adjuvanted seasonal trivalent influenza vaccine.We conducted a single center single-arm study involving 142 subjects (77 adults of 18-60 years and 65 subjects 61 years and above) to test the immunogenicity, safety, and tolerability of a trivalent split influenza vaccine. The vaccine contained 15μg of hemagglutinin of each of the virus strains recommended for the 2010-2011 northern hemisphere winter season (A/California/7/2009 (H1N1)-like strain; A/Perth/16/2009 (H3N2)-like strain; B/Brisbane/60/2008-like strain) in a non-adjuvanted preservative-free formulation. Antibody response to each antigen was measured by hemagglutination inhibition (HI) 21 days after immunization. Subject diary cards and additional telephone interviews were used to assess the safety profile.By day 21 after the vaccination, seroconversion, or a 4-fold antibody increase in HI antibody titers, was detectable against A(H1N1) in 84% and 75% of younger and older adults, against A(H3N2) in 80% and 57%, and against the B influenza strain in 61% and 33%. HI antibody titers of 40 or more were observed against A(H1N1) in 99% and 90% of younger and older adults, against A(H3N2) in 100% and 90%, and against the B influenza strain in 91% and 78%. Pre-vaccination antibody titers were protective against A(H1N1), A(H3N2), and B in 26%, 44% and 33%, respectively of the adults below 61 years and in 27%, 54% and 44% of the subjects of 61 years and above. Local and systemic reactions were more common in younger than in older subjects and the most frequently reported reactions were pain at the injection site (36%), myalgia (24%), and fatigue (15%). Five percent elderly subjects and 1% of younger subjects had mild or moderate unsolicited adverse events such as prolonged ecchymosis or night sweats that resolved within 7 days after vaccination.This single dose trivalent seasonal influenza vaccine generated protective antibodies to all three viral strains and had an acceptable safety profile in both younger and older adults (ClinicalTrials.gov identifier: NCT01147081)." @default.
• W1992023011 created "2016-06-24" @default.
• W1992023011 creator A5002082367 @default.
• W1992023011 creator A5016018500 @default.
• W1992023011 creator A5041171269 @default.
• W1992023011 creator A5062368516 @default.
• W1992023011 creator A5064139482 @default.
• W1992023011 creator A5077338110 @default.
• W1992023011 creator A5079492324 @default.
• W1992023011 creator A5090665271 @default.
• W1992023011 creator A5091591378 @default.
• W1992023011 date "2011-02-01" @default.
• W1992023011 modified "2023-09-27" @default.
• W1992023011 title "Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: A phase III open-label single-arm study" @default.
• W1992023011 cites W1717163386 @default.
• W1992023011 cites W1971824226 @default.
• W1992023011 cites W1975328579 @default.
• W1992023011 cites W1979210826 @default.
• W1992023011 cites W1980908940 @default.
• W1992023011 cites W1982450688 @default.
• W1992023011 cites W1991672332 @default.
• W1992023011 cites W2013947852 @default.
• W1992023011 cites W2021481766 @default.
• W1992023011 cites W2037930292 @default.
• W1992023011 cites W203841483 @default.
• W1992023011 cites W2041753380 @default.
• W1992023011 cites W2045584501 @default.
• W1992023011 cites W2068592034 @default.
• W1992023011 cites W2071507664 @default.
• W1992023011 cites W2079430155 @default.
• W1992023011 cites W2090326173 @default.
• W1992023011 cites W2111299679 @default.
• W1992023011 cites W2111360869 @default.
• W1992023011 cites W2114486596 @default.
• W1992023011 cites W2114924862 @default.
• W1992023011 cites W2167350263 @default.
• W1992023011 cites W2188603275 @default.
• W1992023011 cites W2312463092 @default.
• W1992023011 cites W56574006 @default.
• W1992023011 doi "https://doi.org/10.1016/j.vaccine.2010.11.092" @default.
• W1992023011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21167116" @default.
• W1992023011 hasPublicationYear "2011" @default.
• W1992023011 type Work @default.
• W1992023011 sameAs 1992023011 @default.
• W1992023011 citedByCount "13" @default.
• W1992023011 countsByYear W19920230112012 @default.
• W1992023011 countsByYear W19920230112013 @default.
• W1992023011 countsByYear W19920230112014 @default.
• W1992023011 countsByYear W19920230112015 @default.
• W1992023011 countsByYear W19920230112018 @default.
• W1992023011 crossrefType "journal-article" @default.
• W1992023011 hasAuthorship W1992023011A5002082367 @default.
• W1992023011 hasAuthorship W1992023011A5016018500 @default.
• W1992023011 hasAuthorship W1992023011A5041171269 @default.
• W1992023011 hasAuthorship W1992023011A5062368516 @default.
• W1992023011 hasAuthorship W1992023011A5064139482 @default.
• W1992023011 hasAuthorship W1992023011A5077338110 @default.
• W1992023011 hasAuthorship W1992023011A5079492324 @default.
• W1992023011 hasAuthorship W1992023011A5090665271 @default.
• W1992023011 hasAuthorship W1992023011A5091591378 @default.
• W1992023011 hasConcept C126322002 @default.
• W1992023011 hasConcept C133239900 @default.
• W1992023011 hasConcept C147483822 @default.
• W1992023011 hasConcept C159047783 @default.
• W1992023011 hasConcept C182072434 @default.
• W1992023011 hasConcept C197934379 @default.
• W1992023011 hasConcept C203014093 @default.
• W1992023011 hasConcept C22070199 @default.
• W1992023011 hasConcept C2522874641 @default.
• W1992023011 hasConcept C2777451964 @default.
• W1992023011 hasConcept C2777546802 @default.
• W1992023011 hasConcept C2778375690 @default.
• W1992023011 hasConcept C2779134260 @default.
• W1992023011 hasConcept C2780689484 @default.
• W1992023011 hasConcept C2780868878 @default.
• W1992023011 hasConcept C2908647359 @default.
• W1992023011 hasConcept C2909469553 @default.
• W1992023011 hasConcept C3008058167 @default.
• W1992023011 hasConcept C32611913 @default.
• W1992023011 hasConcept C524204448 @default.
• W1992023011 hasConcept C71924100 @default.
• W1992023011 hasConcept C89623803 @default.
• W1992023011 hasConcept C99454951 @default.
• W1992023011 hasConceptScore W1992023011C126322002 @default.
• W1992023011 hasConceptScore W1992023011C133239900 @default.
• W1992023011 hasConceptScore W1992023011C147483822 @default.
• W1992023011 hasConceptScore W1992023011C159047783 @default.
• W1992023011 hasConceptScore W1992023011C182072434 @default.
• W1992023011 hasConceptScore W1992023011C197934379 @default.
• W1992023011 hasConceptScore W1992023011C203014093 @default.
• W1992023011 hasConceptScore W1992023011C22070199 @default.
• W1992023011 hasConceptScore W1992023011C2522874641 @default.
• W1992023011 hasConceptScore W1992023011C2777451964 @default.
• W1992023011 hasConceptScore W1992023011C2777546802 @default.
• W1992023011 hasConceptScore W1992023011C2778375690 @default.
• W1992023011 hasConceptScore W1992023011C2779134260 @default.
• W1992023011 hasConceptScore W1992023011C2780689484 @default.
• W1992023011 hasConceptScore W1992023011C2780868878 @default.

• next